PROCESS FOR PRODUCING AROMATIC PRIMARY DIAMINES
    3.
    发明申请
    PROCESS FOR PRODUCING AROMATIC PRIMARY DIAMINES 审中-公开
    生产芳香族主要成分的方法

    公开(公告)号:WO2016004867A1

    公开(公告)日:2016-01-14

    申请号:PCT/CN2015/083535

    申请日:2015-07-08

    申请人: RHODIA OPERATIONS

    IPC分类号: C07C209/26 C07C211/18

    摘要: A process for the production of aromatic primary amines, by reacting an aromatic dialdehyde with hydrogen and ammonia or an ammonia-liberating compound, in the presence of a hydrogenation catalyst and an amine, wherein the molar ratio of the amine to the aromatic dialdehyde is no less than 1: 4 at the start of the reaction.

    摘要翻译: 一种通过芳族二醛与氢和氨或释放氨的化合物在氢化催化剂和胺的存在下反应生产芳族伯胺的方法,其中胺与芳族二醛的摩尔比不是 在反应开始时小于1:4。

    ZUR REDUKTIVEN AMINIERUNG VON ALDEHYDEN
    5.
    发明申请
    ZUR REDUKTIVEN AMINIERUNG VON ALDEHYDEN 审中-公开
    对于还原胺化醛

    公开(公告)号:WO2015124413A1

    公开(公告)日:2015-08-27

    申请号:PCT/EP2015/052028

    申请日:2015-02-02

    申请人: BASF SE

    IPC分类号: C07C209/26 C07C211/29

    CPC分类号: C07C209/26 C07C211/29

    摘要: Verfahren zur reduktiven Aminierung durch Umsetzung einer Carbonylverbindung mit einem sekundären Armi und Wasserstoff, dadurch gekennzeichnet, dass die Umsetzung kontinuierlich durchgeführt wird und das Reaktionsgemisch, welches die Carbonylverbindung, das sekundäre Armi und Wasserstoff enthält, zunächst mit einem sauren Festbett und danach mit einem Festbett des Hydrierkatalysator (im Nachfolgenden Hydrierfestbett genannt) in Kontakt gebracht wird.

    摘要翻译: 通过用二次阿尔米海诺和氢的羰基化合物反应为还原胺化的方法,其特征在于所述反应是连续进行的,将反应混合物中,先用一种酸性固定床并且此后含有仲阿尔米海诺的羰基化合物和氢与固定床 氢化催化剂(以下简称Hydrierfestbett)抵接。

    IMPROVED PROCESS FOR THE REDUCTIVE AMINATION AND SELECTIVE HYDROGENATION OF SUBSTRATES CONTAINING A SELECTED HALOGEN
    6.
    发明申请
    IMPROVED PROCESS FOR THE REDUCTIVE AMINATION AND SELECTIVE HYDROGENATION OF SUBSTRATES CONTAINING A SELECTED HALOGEN 审中-公开
    用于选择性氢化物的底物的还原胺化和选择性加氢的改进方法

    公开(公告)号:WO2015032653A1

    公开(公告)日:2015-03-12

    申请号:PCT/EP2014/068083

    申请日:2014-08-26

    申请人: TAMINCO

    摘要: Disclosed is a process for performing a chemical reaction selected from reductive amination and hydrogenation of a first functional group in an organic feed substrate, which feed substrate comprises at least one further functional group containing a halogen atom, wherein the halogen atom is selected from the list consisting of chlorine, bromine, iodine, and combinations thereof, in the presence of hydrogen and a heterogeneous catalyst comprising at least one metal from the list of Pd, Rh, and Ru, together with at least a second metal from the list consisting of Ag, Ni, Co, Sn, Cu and Au. The process is preferably applied for the reductive amination of 2-chloro- benzaldehyde to form 2-chloro-benzyldimethylamine, as an intermediate in the production of agrochemically active compounds and microbiocides of the methoximinophenylglyoxylic ester series. Further disclosed is a composition rich in 2-chloro-benzyldimethylamine, further comprising an amount of 2- chloro-benzyl alcohol and being low in chlorotoluene isomers.

    摘要翻译: 公开了一种用于进行选自有机原料底物中的第一官能团的还原胺化和氢化的化学反应的方法,该进料底物包含至少一个含有卤素原子的另外的官能团,其中所述卤素原子选自列表 由氯,溴,碘及其组合组成,在氢存在下和包含来自Pd,Rh和Ru列表中的至少一种金属的非均相催化剂以及来自列表中的至少一种第二金属由Ag ,Ni,Co,Sn,Cu和Au。 该方法优选用于2-氯 - 苯甲醛的还原胺化以形成2-氯 - 苄基二甲胺,作为生产邻氨基苯基乙醛酸酯系列的农业化学活性化合物和杀微生物剂的中间体。 还公开了富含2-氯 - 苄基二甲基胺的组合物,其进一步包括一定量的2-氯 - 苄基醇,并且氯代甲苯异构体低。

    UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS
    8.
    发明申请
    UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS 审中-公开
    尿素化合物及其作为酶制剂的用途

    公开(公告)号:WO2014017936A2

    公开(公告)日:2014-01-30

    申请号:PCT/PT2013000048

    申请日:2013-07-24

    摘要: A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

    摘要翻译: 具有以下结构的化合物:或其药学上可接受的盐或衍生物。 该化合物可用于治疗或预防选自食欲调节,肥胖症,代谢病症,恶病质,厌食症,疼痛,炎症,神经毒性,神经创伤,中风,多发性硬化症,脊髓损伤,帕金森病,左旋多巴诱导的病症 运动障碍,亨廷顿舞蹈病,吉莱斯德拉图雷特综合征,迟发性运动障碍,肌张力障碍,肌萎缩侧索硬化,阿尔茨海默病,癫痫,精神分裂症,焦虑症,抑郁症,失眠,恶心,呕吐,酒精紊乱,药物成瘾如阿片制剂,尼古丁, 酒精和精神兴奋剂,高血压,循环休克,心肌再灌注损伤,动脉粥样硬化,哮喘,青光眼,视网膜病,癌症,炎性肠病,急性和慢性肝病如肝炎和肝硬化,关节炎和骨质疏松症。